Stock Events

Stock Events

Aligos Therapeutics 

€4.43
46
-€0.09-2.1% Friday 19:55

Statistics

Day High
4.56
Day Low
4.36
52W High
11.2
52W Low
3.48
Volume
-
Avg. Volume
-
Mkt Cap
27.63M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-1.89
-1.3
-0.71
-0.12
Expected EPS
-1.8895123416000001
Actual EPS
N/A

Financials

-927.12%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.88MRevenue
-17.44MNet Income

Analyst Ratings

$30.54Average Price Target
The highest estimate is 36.42.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5WK0.STU. It's not an investment recommendation.
Palantir Technologies
7
PLTR
NVIDIA
6
NVDA
Mobileye Global
6
MBLY
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.2B
Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics for diseases with a similar focus to Aligos, making them direct competitors in the RNAi and NASH space.
Moderna
MRNA
Mkt Cap58.11B
Moderna is involved in mRNA therapeutics, a space that overlaps with Aligos's work on liver diseases, including hepatitis B, positioning them as competitors in the biotech sector.
Vir Biotechnology
VIR
Mkt Cap1.93B
Vir Biotechnology specializes in infectious diseases, including hepatitis B, which is a direct area of focus for Aligos, making them competitors in the infectious disease market.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a strong portfolio in liver diseases, including hepatitis B and NASH, directly competing with Aligos's therapeutic areas.
Arbutus Biopharma
ABUS
Mkt Cap1.02B
Arbutus Biopharma is focused on developing cures for hepatitis B, directly competing with Aligos in the HBV therapeutic area.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech SE, though known for their COVID-19 vaccine, also works on infectious disease therapeutics, overlapping with Aligos's focus areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals has expanded into liver diseases, including NASH, positioning them as competitors to Aligos in the liver disease space.
Novartis
NVS
Mkt Cap304.1B
Novartis AG has a broad portfolio that includes treatments for liver diseases, making them a competitor in the broader pharmaceutical market against Aligos.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a diverse drug portfolio that includes treatments for infectious diseases, potentially competing with Aligos in areas like hepatitis B.

About

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Show more...
CEO
Lawrence Blatt
Employees
82
Country
United States
ISIN
US01626L2043
WKN
000A40LQ4

Listings

STU
DE
5WK0.STU
MU
DE
5WK.MU
F
DE
5WK0.F
MU
DE
5WK0.MU

0 Comments

Share your thoughts

FAQ

What is Aligos Therapeutics stock price today?▼
The current price of 5WK0.STU is €4.43 EUR — it has decreased by -2.1% in the past 24 hours. Watch Aligos Therapeutics stock price performance more closely on the chart.
What is Aligos Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Aligos Therapeutics stocks are traded under the ticker 5WK0.STU.
Is Aligos Therapeutics stock price growing?▼
5WK0.STU stock has fallen by -14.9% compared to the previous week, the month change is a -26.37% fall, over the last year Aligos Therapeutics has showed a -51.37% decrease.
What is Aligos Therapeutics market cap?▼
Today Aligos Therapeutics has the market capitalization of 27.63M
When is the next Aligos Therapeutics earnings date?▼
Aligos Therapeutics is going to release the next earnings report on November 05, 2026.
What were Aligos Therapeutics earnings last quarter?▼
5WK0.STU earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.95 EUR resulting in a +87.2% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Aligos Therapeutics revenue for the last year?▼
Aligos Therapeutics revenue for the last year amounts to 1.88M EUR.
What is Aligos Therapeutics net income for the last year?▼
5WK0.STU net income for the last year is -17.44M EUR.
How many employees does Aligos Therapeutics have?▼
As of September 12, 2026, the company has 82 employees.
In which sector is Aligos Therapeutics located?▼
Aligos Therapeutics operates in the Health & Wellness sector.
When did Aligos Therapeutics complete a stock split?▼
The last stock split for Aligos Therapeutics was on August 19, 2024 with a ratio of 1:25.
Where is Aligos Therapeutics headquartered?▼
Aligos Therapeutics is headquartered in SOUTH SAN FRANCISCO, United States.